Third Harmonic Bio

Clinical-stage company developing a first-in-class, highly selective, oral KIT inhibitor for treatment of severe allergy and inflammation. Learn more

Launch date

2019

Employees

Market cap

Enterprise valuation

AUD473m (Public information from Sep 2024)

Cambridge Massachusetts (HQ)

https://thirdharmonicbio.com/

https://twitter.com/3rdharmonicbio https://www.linkedin.com/company/third-harmonic-bio/

Authorizing premium user...